Eli Lilly & Co. (LLY)

141.04
1.50 1.00
NYSE : Health Technology
Prev Close 139.58
Open 139.50
Day Low/High 138.43 / 141.28
52 Wk Low/High 101.36 / 141.97
Volume 1.70M
Avg Volume 3.43M
Exchange NYSE
Shares Outstanding 960.13M
Market Cap 134.02B
EPS 3.10
P/E Ratio 31.02
Div & Yield 2.96 (1.82%)

Latest News

4 Favorite Biotech Stock Picks for 2020

4 Favorite Biotech Stock Picks for 2020

The Medical Technology Stock Letter's top pick rose 357% in 2019.

3 Powerhouse Pharma Stock Favorites

3 Powerhouse Pharma Stock Favorites

These healthcare stalwarts look attractive for growth and income.

Lilly Raised at Morgan Stanley

Eli Lilly Has the Base to Support a New Rally

Eli Lilly Has the Base to Support a New Rally

Shares of the pharmaceutical company received a quant upgrade Monday.

Jim Cramer: Nothing's Changed, Except the Prices

Jim Cramer: Nothing's Changed, Except the Prices

The market is throwing a Halloween sale right now that it doesn't need to throw, and that's an opportunity.

Jim Cramer: Drug Stocks Are Too Cheap

Jim Cramer: Drug Stocks Are Too Cheap

These stocks are priced for total imperfection. That's just what you want.

Jim Cramer: The Soundness of My Methods

Jim Cramer: The Soundness of My Methods

A little bit of luck and a lot of homework can go a long way to make Big Money out of Mad Money. It's buying a Biogen, a Centene, or a Bristol-Myers that could do just that for you.

6 Top Biopharmaceutical Stock Picks You Should Know About

6 Top Biopharmaceutical Stock Picks You Should Know About

The aging population is creating a massive tailwind for companies that provide cutting-edge health care.

Jim Cramer: How to Survive This Violent Rotation

Jim Cramer: How to Survive This Violent Rotation

Emotions and panic must be checked at the door, if you are going to be a successful investor, especially right now.

A Sagging Drugmaker and Lagging Pet Health Name Both Worth Looks

A Sagging Drugmaker and Lagging Pet Health Name Both Worth Looks

Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.

Trading Apple and Netflix, Beyond Meat Earnings: Market Recon

Trading Apple and Netflix, Beyond Meat Earnings: Market Recon

Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.

Here's a Prescription for Eli Lilly Stock: Don't Swallow Yet

Here's a Prescription for Eli Lilly Stock: Don't Swallow Yet

With prices in a downtrend with a $95 price target, hold off on purchases until prices hold for the drugmaker.

My 3 Predictions for the Second Half of 2019

My 3 Predictions for the Second Half of 2019

Watch the Russell 2000, housing activity, and mergers and acquisitions.

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.

A Handful of Small Biotechs That Make for Merger Chatter

A Handful of Small Biotechs That Make for Merger Chatter

The names include a veterinary drug concern plus companies with successful drugs on the market.

IPO Gives Chinese Couple a 'Hansoh' Sum

IPO Gives Chinese Couple a 'Hansoh' Sum

The initial public offering of Hansoh Pharmaceutical Group made the Chinese couple Zhong Huijuan and Sun Piaoyang the richest in the nation.

Eli Lilly Broke Below the 200-Day Average to Change the Narrative to Bearish

Eli Lilly Broke Below the 200-Day Average to Change the Narrative to Bearish

Let's step back and look at the bigger picture through charts and indicators.

Jim Cramer: A Tale of Two Stocks

Jim Cramer: A Tale of Two Stocks

I want you to remember Eli Lilly and Johnson & Johnson the next time you are about to dump a stock because of some bits of bad news.

Thor Industries and Eli Lilly Offer a Tale of Two Stocks

Thor Industries and Eli Lilly Offer a Tale of Two Stocks

The charts of the maker of recreational vehicles are bearish, while the drugmaker appears to be a buy

China's Drugmakers Under Scrutiny After Stanford Admissions Scandal

China's Drugmakers Under Scrutiny After Stanford Admissions Scandal

Chinese authorities are auditing the books of 77 drugmakers, including three multinationals, they say were selected at random. Were they motivated by embarrassment over a college-admissions payment made by a Chinese pharmaceuticals' tycoon?

Teva Pharmaceuticals CEO: Stock on Track for 2020 Turnaround

Teva Pharmaceuticals CEO: Stock on Track for 2020 Turnaround

But is a Teva turnaround still coming after the stock's 70% loss in the past five years?

Jim Cramer: Diversification Is Good for Offense, Not Just Defense

Jim Cramer: Diversification Is Good for Offense, Not Just Defense

This health care selloff shows the value of diversification to protect our portfolios -- and to go on the offensive and find bargains.

Jim Cramer: Want a Snapshot of the Economy? Look at the Rails

Jim Cramer: Want a Snapshot of the Economy? Look at the Rails

When you see that money pouring out of the market it is going to be looking for a home. The home will most likely want some economic sensitivity.

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

In this day and age, companies must be 'disruptors' or get left in the dust.

Activists Aim to Eliminate Dual Role for Allergan CEO Saunders

Activists Aim to Eliminate Dual Role for Allergan CEO Saunders

David Tepper's Appaloosa LP renews calls for changes at the top.

Jim Cramer: How to Win Now, With or Without China

Jim Cramer: How to Win Now, With or Without China

If we can advance without China then who the heck knows where we can go with it.

3 Pet Product Stocks Ready to Be Unleashed: Dogness, Elanco and Zoetis

3 Pet Product Stocks Ready to Be Unleashed: Dogness, Elanco and Zoetis

Pets can bring significant profits to companies that cater to this niche market.